Sanofi continuing with API spinoff despite French on-shoring push, tensions with union — Reuters
The question of where and by whom drugs’ active ingredients are manufactured was a fairly niche issue back in February, when new Sanofi CEO Paul Hudson first said he would spin off the French giant’s active pharmaceutical ingredient (API) business into its own public company as part of his strategic rethink of the long-laboring drugmaker.
He likely did not imagine that it would soon become a national security question for many countries as a pandemic threatened global supply lines and a vaccine arms race underscored the advantage those with in-country pharmaceutical manufacturing capacity had. Or that French President Emmanuel Macron would stand in a teal facemask at their own French facilities and tell broadcasters about the need to keep production in France.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
